Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc Presents Positive Interim Clinical Data for CLN6 Batten Disease Conference Call Transcript

Aug 01, 2019 / 12:30PM GMT
Release Date Price: $12.36
Operator

Good morning, ladies and gentlemen, and welcome to the Amicus conference call to discuss interim clinical data in CLN6 Batten disease. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Vice President of Investor Relations and Corporate Communications, Ms. Sara Pellegrino. You may begin.

Sara Pellegrino
Amicus Therapeutics, Inc. - VP of IR & Corporate Communications

Good morning. Thank you for joining our conference call to discuss the positive interim clinical data for the Amicus AAV gene therapy and CLN6 Batten disease. Speaking on today's call from Amicus, we have John Crowley, Chairman and Chief Executive Officer; Dr. Jay Barth, Chief Medical Officer; and Dr. Jill Weimer, Senior Vice President of Discovery, Research and Gene Therapy Science. Also joining from the Q&A are Bradley Campbell, President and Chief Operating Officer; Daphne Quimi, Chief Financial Officer; Dr. Hung Do, Chief Science Officer; and Dr. Jeff Castelli, Chief Portfolio Officer and Head of Gene

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot